2–5×
Blood NAD+ It Raises
Human placebo-controlled trials consistently show NR/NMN roughly double blood NAD+ (up to ~5× at high NR doses). Repeated and consistent across labs and countries.
1
Drug Company That Got the FDA to Act
Metro International Biotech — co-founded by NMN's own most famous researcher — filed to develop NMN as a patented drug. The FDA used that filing to try to pull NMN off the supplement shelf.
Japan & China
Never Stopped Selling It
NMN has been an officially recognized food ingredient in Japan since 2020 and is manufactured at industrial scale in China — while the US argued about a technicality.
$30–80
Monthly Cost (Pills)
A studied dose of NR or NMN. IV NAD+ drips run $200–$2,000 per session on far thinner evidence — the price gap doesn't track the proof.
This is not a conspiracy theory — it's a documented regulatory timeline, and it's the single most important thing to understand before reading anything else on this page. A cheap, widely-available supplement got legally reclassified as off-limits right after someone tried to patent it.
The Setup
2016–2019
Metro International Biotech LLC was founded to develop a proprietary NMN formulation (MIB-626) as a patentable prescription drug — co-founded by David Sinclair, the Harvard researcher most publicly associated with NMN. NMN itself had already been sold as a supplement in the US since at least 2017.
The FDA Move
Nov 2022
The FDA ruled NMN was excluded from the legal definition of a dietary supplement — because it had been "authorized for investigation as a new drug" first. That's the same legal trapdoor (the DSHEA "drug exclusion clause") that can turn any popular supplement into a company's private patent territory the moment a drug filing exists for it.
The Industry Fight
2023–2024
The Natural Products Association sued the FDA, arguing NMN was already lawfully marketed years before any drug investigation. The FDA had itself previously acknowledged an NMN supplement notification without objection — then reversed itself to favor the drug path.
The Reversal
Sept 2025
Under legal pressure, the FDA reversed course and declared NMN lawful again — acknowledging it had been sold as a supplement since 2017, before any drug investigation began. Translation: the original exclusion was built on a timeline the FDA's own evidence didn't support.
The pattern to notice: a cheap, over-the-counter molecule (NMN pills run $30–70/month) came within one regulatory letter of being pulled from the market entirely — not because it was shown to be unsafe or ineffective, but because a company wanted to sell a patented, prescription-only version of the same molecule. A prescription NMN drug (MIB-626) can be priced however a patent holder wants; an open supplement market selling the same molecule for $30/month cannot. The FDA's 2022 letter would have handed one company's drug program a three-year head start with the competition legally banned. Whether or not that was the FDA's intent, it's exactly the effect the "drug exclusion clause" produced — and it's why the same legal trapdoor is worth watching on every other cheap, popular supplement. The reversal came only after the supplement industry sued and produced evidence the FDA's own preclusion timeline was wrong.
The US regulatory fight was a US-only story. NMN never had a legal cloud over it in the countries that actually manufacture and consume the most of it — a useful reality check on how much weight to put on any single country's regulator.
Japan — Official Food Ingredient
Since 2020
Japan's Ministry of Health, Labour and Welfare added NMN to its "non-medical drug" food list in March 2020. NMN is now sold openly in Japanese pharmacies, department stores and health clinics — no supplement category has grown faster there.
China — Manufacturing Base
Global Supply
Chinese manufacturers (Huzhou Yihui Biotechnology, ABA Chemicals, SyncoZymes) supply much of the world's NMN raw material and co-author the international clinical trials below. The 2025 FDA reversal letter itself went to a Shanghai supplier.
Singapore & India — Real Trials
Cross-Border RCT
A rigorous 80-person, dose-ranging, placebo-controlled trial was jointly run out of the National University of Singapore and Indian research sites, registered on both ClinicalTrials.gov and India's CTRI — genuinely international science, not a US-only evidence base.
The Contrast
Zero Ban Abroad
No major NMN-manufacturing or NMN-consuming country outside the US treated it as a banned or restricted substance during 2022–2025. The exclusion fight was a US patent-and-supplement-law technicality — not a global safety concern.
There's one fact almost everyone agrees on and one real gap worth naming plainly. The fact: swallowing NMN or NR reliably raises the NAD+ in your blood, in trial after trial, in multiple countries. The gap: raising a lab number is not automatically the same as feeling dramatically better or living longer — and that's where the human trial data is thinner and the effects are smaller. This chart sets expectations honestly before the detail below; it's not a verdict against the compound, it's an honest read of where the science currently stands. (According to PubMed; citations and DOIs in the footer.)
Raising NAD+ Levels
Repeatedly proven in placebo-controlled human trials across the US, Europe, Japan and Singapore/India — NR and NMN reliably push blood NAD+ up. This part is settled.
Real Clinical Benefit
Genuine positive signals in specific populations — walking speed, insulin sensitivity, blood pressure, airway inflammation — alongside some null results. Small trials, real but uneven wins.
Long-Term Human Lifespan Data
Spectacular in mice; no long-duration human trial has run long enough to test it directly. Not disproven — simply not yet tested at that scale, because that trial is expensive and nobody with a $30/month generic has the incentive to fund it.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme in every living cell. It shuttles energy in your mitochondria and is the required fuel for the "repair crew" enzymes — sirtuins and PARPs — that fix DNA and manage stress. The catch: your NAD+ supply drops with age. You can't absorb NAD+ itself well by mouth, so you take a precursor (a building block) — NMN or NR — that your body converts into NAD+. (According to PubMed.)
The Cell's Repair Fuel
Sirtuins
Each of the 7 sirtuins — the DNA-repair and longevity enzymes — requires NAD+ to work. Less NAD+ means a slower repair crew. This is the core mechanism the whole field is built on.
It Falls With Age
↓ With Age
NAD+ declines in skin, blood, muscle, liver and brain as we get older — the observation that launched the whole "top it back up" idea. The decline is well documented; whether refilling it changes aging outcomes is the frontier being actively studied worldwide.
NMN vs NR
2 Routes
NR is one step further back in the pathway; NMN is one step closer to NAD+ (NR → NMN → NAD+). Both raise blood NAD+ in trials. NR never had a US regulatory cloud; NMN did, briefly, for reasons explained above — not because of new safety data.
It Reliably Raises NAD+
~2×
In a placebo-controlled crossover, 1,000 mg/day NR roughly doubled blood NAD+ in healthy middle-aged and older adults and was well tolerated. The "it boosts NAD+" claim is the best-proven thing on this page.
This is the dream people are buying: more energy, slower aging, a longer healthy life. The precursors do what they say on the molecule (NAD+ goes up), and multiple international trials show real downstream signals — lower blood pressure, less airway inflammation, better walking speed. The lifespan claim specifically hasn't been tested in a long-duration human trial yet — and as the money section above explains, that trial is expensive and nobody profits enough from a $30/month generic to fund it at scale.
Lower Blood Pressure (signal)
↓ BP
In the same NR trial, blood pressure and arterial stiffness trended down — a promising cardiovascular signal the authors said warrants larger trials. A real early signal, worth funding further.
Less Airway Inflammation (COPD)
−53%
In 40 COPD patients, 6 weeks of NR cut a key airway inflammation marker (IL-8) by ~53% vs placebo, more than doubled blood NAD+, and hinted at reduced "epigenetic aging." Small but promising.
Walking & Biological Age (NMN, Singapore/India)
Held Steady
In an 80-person dose-ranging RCT, blood biological age rose in the placebo group but stayed flat in every NMN-treated group over 60 days, and walking distance improved significantly at 300–900 mg/day. One of the cleanest positive human results on the page.
Walking & Sleep (NMN, Japan)
Walk Speed
In 60 older adults, 250 mg/day NMN for 12 weeks raised blood NAD+, modestly improved 4-meter walking speed and sleep quality — though it missed its primary stepping-test endpoint. A mixed but real result, not a failure.
This is where the strongest specific human findings live, from trials run across the US, Japan, China, Singapore and India. The famous flagship result (NMN in prediabetic women) sits alongside several trials with smaller or null findings in different populations — that's the real, honest shape of the evidence: real wins in some groups, no results in others, which is normal for a compound this early in its human-trial life.
| # |
Study |
Type / n |
What It Found |
| 1 |
NMN in prediabetic women — muscle insulin sensitivity (Yoshino/Klein, Science)
|
RCT
n=25, 10 wks, 250 mg/d |
Positive
Muscle insulin sensitivity & insulin signaling improved with NMN, not placebo. The field's flagship human win — small, women-only, prediabetic, but real. |
| 2 |
NMN, walking & biological age — Singapore/India dose-ranging RCT
|
RCT
n=80, 60 days, 300–900 mg/d |
Positive
Best walking-distance gains and best-held biological age at 600–900 mg/day. International, well-designed, dose-dependent. |
| 3 |
NR for peripheral artery disease — the NICE trial (walking)
|
RCT
n=90, 6 mo |
Modest +
NR improved 6-minute walk distance vs placebo (~+18 m; +31 m in adherent patients). Resveratrol added nothing. Worth a bigger trial. |
| 4 |
NMN, muscle & liver in middle-aged/elderly (meta-analysis)
|
Meta-analysis |
Small +
Pooled data (largely from Chinese trial sites) showed better gait speed and lower ALT (a liver marker) & insulin resistance. The authors' own conclusion: "an encouraging and considerable [candidate] for anti-aging." |
| 5 |
NMN safety in healthy middle-aged Japanese men
|
Trial
n=11, 8 wks, 250 mg/d |
Safe; minor
Well tolerated; raised NAD+; modestly blunted post-meal insulin spikes only in those who over-secreted insulin. Small study, safety confirmed. |
| 6 |
NMN in elderly diabetic men with frailty — Osaka University
|
RCT
n=14, 24 wks, 250 mg/d |
No benefit (primary)
Safe over 24 weeks (the longest trial on this page); did not improve grip strength or walking speed in this small, frail, elderly diabetic group. Led by Shin-Ichiro Imai, one of the field's founding NAD+ researchers — an honest null result from a rigorous, non-US-only team. |
| 7 |
NR + CoQ10 in chronic kidney disease — exercise capacity
|
RCT
n=25, 6 wks each |
No benefit
NR shifted metabolism & lipids but did not improve peak oxygen uptake or work efficiency vs placebo in this sicker population. An honest null result. |
| 8 |
Metabolic activators (incl. NR) in Alzheimer's — cognition
|
RCT
84 days |
Combo only
A 4-ingredient combo (NR + serine + NAC + carnitine) improved cognitive scores — but you can't credit NR alone in a cocktail. |
The priciest route also has the least human-trial backing of the three — and the price gap tracks clinic margins, not proof. Clinics sell IV NAD+ infusions and injections for fatigue, "brain fog," addiction recovery and anti-aging at $200–$2,000 a session. The molecule reliably floods into the bloodstream; what's genuinely unproven is whether paying 10–50× the price of a pill buys any additional benefit.
Raises NAD+ Fast
Hours
A pilot study tracked NAD+ and its metabolites during a 6-hour, 750 mg IV infusion — confirming it floods the system quickly. The molecule going up isn't in doubt.
Claims Outrun the Trials
Few RCTs
Marketed for depression, anxiety, addiction, fatigue and athletic performance — but these claims "largely lack the clinical evidence base." Rigorous RCTs are scarce for the IV-drip promises specifically — a real gap clinics should be honest about.
Pills May Be Just as Smart
IV vs Oral
A randomized pilot comparing IV NR vs IV NAD+ suggested IV NR raised NAD+ more efficiently and with fewer infusion reactions — and oral precursors raise NAD+ for a fraction of the cost, with a much longer safety record.
The Infusion Discomfort
Go Slow
Pushed too fast, IV NAD+ commonly causes chest pressure, flushing, nausea and cramping — which is why drips are run slowly over hours. Real inconvenience for a route with the thinnest outcome data.
If you're deciding how to spend on NAD+, the gap between the routes is enormous — and it does not track the evidence. The cheapest options (pills) have the deepest international trial record; the most expensive (IV) has the thinnest. Approximate 2026 US prices.
Best Evidence/$
NR (e.g. Tru Niagen), oral
$40–80
per month (300–1,000 mg/day)
The deepest safety & trial data of any route; never had a US regulatory cloud
NMN, oral
$30–70
per month (250–900 mg/day)
The longevity world's favorite; legal again (2025) after a fight explained above
Plain niacin / B3 (the cheap precursor)
~$5
per month
Also raises NAD+; what one skeptic MD takes instead
Thin Evidence
NAD+ shots (IM/SubQ)
$75–250
per shot
Faster into blood; little outcome data
Priciest, Thinnest Data
IV NAD+ drip (clinic)
$200–2,000
per session ($10k–25k/yr w/ maintenance)
2–4 hrs per drip; few dedicated RCTs
The FDA has not approved a specific "anti-aging" dose (it doesn't approve doses for anti-aging use, full stop — that's not unique to NAD+), so these are the patterns from the human trials and the longevity community — reported for information, not as medical advice. Doses are locked to the ranges actually used in the studies above.
NR (standard)
300–1,000 mg/day
The trial range (Martens used 1,000 mg/day). Usually once daily in the morning.
NMN (standard)
250–900 mg/day
Most trials used 250–300 mg/day; the Singapore/India dose-ranging trial found 600–900 mg most effective. Taken in the morning.
Sinclair variant
1,000 mg NMN, AM, with fat
David Sinclair (PhD) reports 1 g NMN each morning in yogurt — a personal protocol, above typical trial doses (he has commercial ties to the drug-development side of NMN; see the money and doctors sections).
Critical caveat
No official "anti-aging" dose exists
Doses are extrapolated from trials, not from a single approved standard. Safety above trial doses (well beyond 1–3 g/day) is less studied. More is not proven to be better.
The FDA is one country's regulator, weighing one country's supplement law against one company's drug-patent filing — not a global scientific verdict. NMN went through a real regulatory rollercoaster in the US specifically, driven by the drug-patent conflict detailed above, and reversed in September 2025. NR was never touched by any of it. Neither compound was ever restricted internationally.
FDA — NMN (2025 reversal)
Lawful supplement again (Sept 29, 2025)
The FDA reversed its 2022 exclusion after acknowledging NMN was marketed as a supplement since 2017 — before the drug investigation the original exclusion relied on. This is the FDA's own position; treat it as one regulator's call, not a scientific verdict on the molecule.
FDA — NR (Niagen)
Legal throughout; GRAS & NDI-notified
Nicotinamide riboside (branded Niagen) has been sold legally as a dietary ingredient with FDA "no objection" notifications the whole time — it never got caught in a drug-patent conflict.
Japan & China — No Ban, Ever
Sold openly the entire time
Japan classified NMN as a legal food ingredient in 2020 and never revisited that; China manufactures it at industrial scale for global export, including to US brands. The US supplement-law fight had zero counterpart abroad.
Few supplements have a cleaner "two camps" split than NAD+. Real-world use: NMN/NR are wildly popular in the longevity and biohacker community, where users report more energy and better recovery — lived experience worth noting alongside the controlled data, not dismissed as "not evidence." The two most-cited public voices sit on opposite sides — one a researcher with a commercial drug stake, one a skeptic MD who reads every trial — both weighed against PubMed below, and against who actually profits from each answer.
David Sinclair, PhD
Harvard Geneticist (PhD, not an MD) · NAD+/sirtuin researcher
The field's leading proponent. He argues NAD+ decline drives aging, takes 1 g NMN every morning, and frames precursors as activating the sirtuin repair system. He co-founded Metro International Biotech — the company developing a patented NMN drug that triggered the 2022 FDA exclusion fight described above — a direct commercial stake worth weighing against his advocacy.
vs PubMed: the mechanism (NAD+ → sirtuins → repair) is well-supported, and precursors do raise NAD+ with real downstream signals. The multi-decade lifespan claim specifically hasn't been tested in a long-run human trial — a gap that exists partly because his own drug program benefits more from a patented pathway than a funded open trial of the cheap generic.
Dr. Brad Stanfield, MD
GP, New Zealand · evidence-based longevity · no commercial NAD+ stake
The skeptic, and the one with nothing to gain either way. He read all ~18 NMN human studies available at the time and concluded the early evidence was "not overly convincing" on muscle-tissue NAD+ specifically, with only 4 of 28 pooled metabolic measures beating placebo. He switched from NMN/NR to cheap niacin and says so publicly.
vs PubMed: a fair match with the trial record at the time he wrote it — small, short, uneven studies. Newer international trials (Singapore/India dose-ranging, the COPD trial) have since added stronger positive signals than were available when he made that call. He also flags Sinclair's commercial conflicts directly, which this page verifies independently above.
At studied doses, oral NAD+ precursors are consistently well tolerated across every country that's trialed them — this is one of their genuine strengths, and the honest cautions below are about real unknowns, not proven harms.
Oral: consistently well tolerated
Across human trials in the US, Japan, Singapore and India — including 6-month and high-dose (up to 3,000 mg/day NR) safety trials — NR and NMN were well tolerated. When side effects occur they're mild: nausea, flushing, stomach upset, headache.
The honest unknown: very long-term
Most human trials run 2–24 weeks; the longest on this page (Osaka, PMID 36443648) ran 24 weeks safely. We don't yet have multi-year safety data. One MD also notes NMN can partly convert to niacin in the gut, and very-high-dose niacin carries cardiovascular concerns — a reason to be wary of extreme mega-doses specifically, not of the studied range.
The cancer debate (theoretical)
Because NAD+ fuels cell growth and repair, researchers debate whether boosting it could, in theory, also feed existing tumors. This is an open scientific question, not a documented human risk — but it's why anyone with active cancer should loop in their oncologist before starting.
Who should be careful
Anyone with active or recent cancer (talk to your oncologist first), pregnant or breastfeeding (unstudied), and anyone on prescription meds — check for interactions. The IV route adds infection/sterility and infusion-reaction risks; use a qualified provider.
The one thing to remember: the pills are low-risk and consistently well tolerated across every country that's studied them at the doses people actually take — the real, honest cautions are the still-open
very-long-term safety question, avoiding extreme mega-doses, and the theoretical cancer-fuel question for people with active cancer. If that's you, or you're pregnant/breastfeeding, loop in a doctor before starting — otherwise, the downside of trying a studied dose is low.
(Safety: NR-SAFE high-dose trial, Song NMN review, Osaka 24-week trial.)
The Bottom Line — In Plain English
NAD+ precursors are a genuine biology story that got tangled up in a US patent fight. Swallow NMN or NR and your blood NAD+ reliably goes up, in trial after trial, in multiple countries — that part is settled. The molecule was never dangerous or fraudulent enough to justify what almost happened to it: the FDA came within one lawsuit of pulling a $30/month generic off shelves right after a competing patented-drug program was filed on the same molecule. Weigh that when you weigh the "unproven" hedges you'll see elsewhere.
What It Is
NAD+ is a coenzyme every cell needs for energy and DNA repair; it falls with age. NMN and NR are building blocks (precursors) your body turns into NAD+.
What It Does
Reliably raises blood NAD+ (~2×, up to ~5× high-dose) in every country that's trialed it. Real downstream benefits: blood pressure, walking speed, insulin sensitivity, held-steady biological age in some populations.
How It's Used
Pills: NR 300–1,000 mg/day or NMN 250–900 mg/day, morning. Also IV drips & shots — 10–50× pricier, thinner trial record.
The Money Story
The FDA moved to exclude NMN from the US supplement market in 2022 right after a company (co-founded by NMN's own leading researcher) filed to patent it as a drug. Reversed 2025 under legal pressure. Japan and China never touched it.
What You Decide
Real, repeated biology; consistently safe at studied doses; genuine early clinical wins in several populations; the multi-decade lifespan question is unfunded, not disproven. You weigh the evidence and the incentives — this page isn't handing you a verdict.
- The best-proven fact: NMN and NR reliably raise blood NAD+ in placebo-controlled human trials run across the US, Japan, China, Singapore and India.
- Follow the money: the FDA tried to exclude NMN from the supplement market in 2022 right after a company co-founded by NMN's leading researcher filed to develop it as a patented drug — and reversed only after a lawsuit forced the issue in 2025.
- Look at every country: Japan classified NMN as a legal food ingredient in 2020 and China manufactures it at industrial scale — neither ever treated it as unsafe or unproven enough to restrict.
- Clinical wins are real and growing: blood pressure, airway inflammation, walking speed, insulin sensitivity, and held-steady biological age in a dose-ranging international trial; some null results too, which is normal at this stage of human research.
- Cost doesn't track evidence: the cheap pills have the deepest data; the $200–2,000 IV drips have the thinnest.
- Two camps, weighed by who profits: Sinclair (PhD) promotes it and holds a commercial drug-patent stake; Stanfield (MD) has no financial stake, read every study, and switched to cheap niacin.
- Consistently well tolerated at studied doses across every country that's trialed it — the honest cautions are unknown very-long-term safety, avoiding mega-doses, and a theoretical cancer-fuel question for people with active cancer.
This page is general information for the person deciding, not medical advice. According to PubMed; full citations and DOIs below.